The IgA Nephropathy Landscape Has Experienced Rapid Changes Over Past Two Years with Increased Use of SGLT2 Inhibitors and Tarpeyo (Calliditas); More Change on The Way with Filspari (Travere) Launch, According to Spherix Global Insights
Content Area
Fierce Pharma: Docs likely to be ‘cautious’ when prescribing GSK’s first-in-class anemia drug Jesduvroq, survey finds
The path to approval was long and winding for a new class of medicines called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. And even after GSK clinched regulatory victory earlier this month, its Jesduvroq may have a hard time swaying doctors in the real world, according to a Spherix Global Insights poll. In early February, Jesduvroq […]
Ardelyx’s Tenapanor (IBSRELA) Becomes a Relevant Player in the Irritable Bowel Syndrome with Constipation Market as the Company Awaits Important Regulatory News for the Drug in Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Surveyed nephrologists indicate enormous unmet need for new drugs to treat hyperphosphatemia and anticipate early adoption if the product is approved by the FDA EXTON, Pa., December 14, 2022 – After receiving an unexpected Complete Response Letter (CRL) from the FDA in July 2021 for tenapanor (marketed as XPHOZAH) to treat hyperphosphatemia, Ardelyx pivoted and […]
U.S. Nephrologists Report Mixed Reactions to the Approval of GSK’s Jesduvroq® (daprodustat) for the Treatment of Anemia in Dialysis Patients, According to Spherix Global Insights
110 U.S. nephrologists provided immediate feedback regarding GSK’s newly approved HIF-PH inhibitor – the first approved in the United States – for the treatment of anemia in dialysis patients. EXTON, Pa., February 9, 2023 – Since 2017, Spherix Global Insights has been monitoring the U.S. renal anemia market landscape, capturing nephrologists’ perceptions and opinions of […]
Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer’s Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets
Spherix Global Insights announces insights pulled from chart audit data from thousands of patients highlighting the evolution of chronic kidney disease (CKD) patient care EXTON, Pa. /January 20, 2023/PRNewswire/ – With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has begun to change notably. Feedback […]
Ardelyx’s Tenapanor (IBSRELA) Becomes a Relevant Player in the Irritable Bowel Syndrome with Constipation Market as the Company Awaits Important Regulatory News for the Drug in Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Surveyed nephrologists indicate enormous unmet need for new drugs to treat hyperphosphatemia and anticipate early adoption if the product is approved by the FDA EXTON, Pa., Dec 14, 2022 /PRNewswire/ – After receiving an unexpected Complete Response Letter (CRL) from the FDA in July 2021 for tenapanor (marketed as XPHOZAH) to treat hyperphosphatemia, Ardelyx pivoted […]
FibroGen/Astellas’ EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, According to Spherix Global Insights
Findings are based on a bi-annual study of 258 European Union & United Kingdom nephrologists EXTON, Pa., December 6, 2022 /PRNewswire/ — After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021 for Roxadustat, FibroGen found success with partner Astellas in Europe. EVRENZO […]
Spherix Global Insights Releases the Titles of Four Abstracts to be Presented at American Society of Nephrology (ASN) Kidney Week 2022
Independently funded research on the role of primary care physicians in CKD care, SGLT2 inhibitors and advancing care for IgA nephropathy patients, disparities in clinical trial enrollment, and lupus nephritis co-management are all covered in Spherix’s abstracts EXTON, Pa., October 18 , 2022 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology, is […]
Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports
Nephrologists are most anticipating sparsentan (Travere, co-marketed with Vifor in EU), with Vertex’s pipeline product VX-147 following closely behind – according to new research from Spherix Global Insights EXTON, Pa., September 21, 2022 /PRNewswire/ — Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of nephrotic syndrome across the world and is considered the […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma, According to New Spherix Report
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs EXTON, Pa., September 12, 2022 /PRNewswire/ — Over the past year, many countries have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in […]
